HRCM
TXMD icon

Hawk Ridge Capital Management’s TherapeuticsMD TXMD Stock Holding History

Hawk Ridge Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-9,676
Closed -$1.17M – 55
2019
Q4 		$1.17M Buy
+9,676
New +$1.39M 0.19% 38

Other funds holding TXMD

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hawk Ridge Capital Management's TXMD Position: Q1 2020 in Review

Hawk Ridge Capital Management sold out of TherapeuticsMD (TXMD) in Q1 2020, closing a stake of 9,676 shares — an estimated $1.17M sold.

Hawk Ridge Capital Management first reported a position in TXMD in Q4 2019 and held it in 1 quarter. The position peaked at $1.17M in Q4 2019. 143 funds tracked by Wall St. Rank hold TXMD as of Q1 2020.

  • Hawk Ridge Capital Management reported no remaining TherapeuticsMD position as of Q1 2020 after selling out during the quarter.
  • Hawk Ridge Capital Management sold 9,676 TherapeuticsMD shares in Q1 2020, an estimated $1.17M.
  • Hawk Ridge Capital Management first reported a position in TherapeuticsMD in Q4 2019 and held it in 1 quarter.
  • Hawk Ridge Capital Management's TherapeuticsMD position peaked at $1.17M in Q4 2019.
  • 143 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2020.

Based on Hawk Ridge Capital Management's 13F filing for Q1 2020, filed 6 May 2020.